BioMedAI · Agent Set 2
Autonomous Drug
Design Agents
ADDA takes validated targets from DBRA and applies generative AI to design, screen, and optimize candidate molecules — reasoning over structure-activity relationships, ADMET profiles, and synthesis feasibility.
In Active Development
70%
Projected faster drug design cycles
Stage 2
Follows DBRA target research output
Development Progress
Active development · Early access Q3 2025
DBRA — Live
ADDA — In Dev
ADDA is Stage 2 of the BioMedAI pipeline — it receives target validation outputs from DBRA and applies generative AI to molecule design.
Design Workflow
From Validated Target to Lead Candidate
ADDA agents orchestrate the full small molecule and biologics design loop with continuous optimization.
1. Target Input
Input requested drug targets and user constraints.
2. Molecule Generation
Generate candidate molecules optimized for binding affinity and selectivity.
3. Developability Screening
Each candidate is scored and filtered for developability prediction.
4. Lead Ranking
Top candidates are ranked by multi-parameter optimization and synthesis feasibility score.
Planned Capabilities
What ADDA Will Deliver
Target Input
Input requested drug targets and user constraints — including binding site preferences, selectivity requirements, and modality restrictions.
In Development
Molecule Generation
Generate candidate molecules optimized for binding affinity and selectivity using generative AI models across small molecules and biologics.
In Development
Developability Screening
Each candidate is scored and filtered for developability prediction — covering ADMET properties, solubility, stability, and manufacturability.
In Development
Lead Ranking
Top candidates are ranked by multi-parameter optimization and synthesis feasibility score, delivering a shortlist ready for experimental validation.
In Development
Antibody & Biologics Design
Generative design of antibodies, nanobodies, and other biologic modalities — including sequence optimization and structure-based affinity maturation.
Planned
Synthesis Feasibility
Automated retrosynthesis planning and reaction route scoring to assess practical synthetic accessibility before committing to wet-lab validation.
Planned
In Development
Get Early Access to ADDA
We're working with select biopharma teams to co-develop ADDA's capabilities. If you have a drug design challenge, we'd like to hear from you.
Book a Discovery CallStart with DBRA While ADDA Launches
DBRA is live today. Get your target research automated now — and be first in line when ADDA ships.